Prevalence of Restless Legs Syndrome in Patients Treated with Peritoneal Dialysis: Clinical and Biochemical Characteristics among Patients with and without Restless Legs Syndrome ()
1. Introduction
Restless legs syndrome (RLS) is the most prevalent sensorimotor disorder during sleep. The prevalence of RLS is estimated to be 5% - 15% in general [1-3]. The diagnosis of RLS is based on history with standardized clinical criteria, defined by the International RLS Study Group (IRLSSG) [4]. RLS is defined in two categories: idiopathic RLS (iRLS), which refers to familial tendency and no-known background condition while secondary RLS refers to various co morbid conditions, such as iron deficiency, diabetes mellitus, pregnancy, multiple sclerosis (MS), Parkinson’s disease and end stage renal disease (ESRD) [5-12]. Prevalence of RLS in patients undergoing dialysis therapy due to ESRD has a wide range between 6.6% and 83% [13-24] depending on the varying diagnostic criteria applied in those studies, before the final standardization by the IRLSSG criteria. Moreover, this variation has been explained by the improvement of dialytic techniques as well as the pharmacological treatment of the ESRD.
The pathophysiological mechanisms involved in the idiopathic RLS are multifactorial, including dopaminergic dysfunction, spinal cord disinhibiting and dysfunction in the iron metabolism [25-29]. Regarding the secondary RLS in ESRD, iron-vitamin B—folic acid deficiency, DM as well as inadequate peritoneal dialysis (PD) was suggested to be the main risk factors for this condition.
Most of previous prevalence studies among ESRD patients have been conducted in those undergoing hemodialysis (HD) therapy and the results were mainly explained by the known risk factors as described above. To date, only a few studies addressed the prevalence of RLS among ESRD patients undergoing PD. Moreover, the real prevalence of RLS in ESRD, after excluding the patients with other known risk factors, is still unknown.
The aim of the current study was to evaluate the prevalence of RLS in ESRD patients treated with PD without known risk factors and to compare the clinical and biochemical characteristics of RLS patients with subjects without this condition.
2. Methods
2.1. Patients
The study was performed on 200 patients who were on PD treatments due to ESRD for at least 6 months and were followed up by Nephrology Department of Erciyes University Medical Faculty. Patients were also evaluated for RLS in Sleep Disorders Unit of Neurology Department of Erciyes University Medical Faculty. The local ethics committee approved the study protocol. The study was conducted in accordance with the declaration of Helsinki and local laws depending on whichever afforded greater protection to the patients. All the patients gave their informed consent of participation in the study.
We excluded 144 patients from the study who are under 18 years, or have either diabetes mellitus, anemia which was defined as a hemoglobin level < 10 g/dL, iron deficiency which was defined as a transferrin saturation < 20% and a serum ferritin concentration < 100 ng/mL, Multiple Sclerosis, Parkinson’s disease, pregnancy and/ or acute peritonitis because these conditions are important risk factors for symptomatic RLS. Also, patients who have taken medications such as antidepressants, neuroleptics or hypnotics that are known to affect sleep structure and have the sensorimotor symptoms of RLS were excluded.
Finally, 56 patients who fulfilled the inclusion and exclusion criteria were included in the study.
2.2. Data Collection
Firstly, clinical and laboratorial data of 56 patients were collected by the nephrologist of the PD unit. These data contained age, gender, body mass index, etiology of ESRD, smoking, drinking alcohol, use of erythropoietin, use of B complex vitamins and folic acid, duration of peritoneal dialysis, weekly Kt/Vurea, amount of residual urine volume, hemoglobin, serum calcium level, serum phosphorus level, calcium × phosphorus product, serum albumin level, serum iron level, total iron binding capacity, transferrin saturation, serum ferritin level, serum vitamin B12 level and serum folic acid level.
Secondly, all patients were examined by neurologist who were experts in sleep disorders and were evaluated with regard to presence of four essential RLS criteria as defined by the IRLSSG.
2.3. Statistical Analysis
SPSS 15.0 statistic software was used for the statistical analysis. The Kolmogorov-Smirnov test was used to determine the normality of the distributions of the variables. Continuous variables with normal distribution were presented as mean ± standard deviation. Median value was used when normal distribution was absent. Statistical analysis for the parametric variables was performed by the Student’s t test between two groups. The MannWhitney U test was used to compare nonparametric variables between two groups. The qualitative variables were given as percent and the chi-square test and Fisher's exact test were used to compare variables between the two groups. p value of <0.05 was considered to be significant.
3. Results
The mean age of the 56 patients was 47.10 ± 12.42 years. Thirty one of the 56 patients were male and the rest of them were female. RLS was found in 13 (23.2%) of 56 PD patients. The most frequent cause of the etiology of end-stage renal disease was hypertension. The most of the patients had average peritoneal transport characteristics. The demographic, clinical, and biochemical parameters of the patients are summarized in Table 1.
Demographic, clinical, and biochemical parameters of the 13 patients with RLS are compared to 43 patients without RLS in Table 2. The use of vitamin B complex + folic acid supplements was significantly lower in patients with RLS than in those without RLS (69.2% vs 97.7%; p = 0.008). Although there was no statistically significant difference between two groups, folic acid levels were found in lower levels in patients with RLS than in those without RLS. On the other hand, there was no significant difference between patients with RLS and those without RLS in regard to age, gender, body mass index, cause of ESRD, peritoneal membrane transport characteristic, smoking, drinking, use of erythropoietin, duration of PD, hemoglobin, serum calcium, serum phosphorus, serum albumin, levels of serum iron, total iron binding capacity, ferritin, and vitamin B12, transferrin saturation, weekly Kt/Vurea value, and amount of residual urine volume (p > 0.05).
4. Discussion
The prevalence of RLS in dialysis populations appears to be greater than in the general population although there is a wide variation, ranging between 6.6% and 83% [13-24]. Also, in previous studies which most of them were made in HD patients, no significant difference has been found between HD and PD patients in terms of RLS prevalence
Table 1. Demographic, clinical and biochemical characteristics of patients on peritoneal dialysis.
ESRD: end-stage renal disease, PET: peritoneal equilibration test.
[13,17,30-32]. Our study group was constituted from under PD patients and prevalence of RLS was found 23.2 % when the other risk factors except for ESRD for secondary RLS were excluded. To date, only few studies evaluated the prevalence of RLS in PD patients [17,33, 34] and in those studies, RLS prevalence has been found between 19.7% [33] and 69.2% [34]. In the whole prevalence studies in uremic patients, RLS has been found more common than general population. This condition has been tried to be explained by increased frequency in presence of some risk factors such as iron deficiency, DM, vitamin and folic acid deficiencies in uremic patients. In present study, we studied the prevalence of RLS in ESRD patients treated with PD after risk factors that have been known to be frequently related with RLS were excluded. Consequently, prevalence of RLS in PD patients was found more common than general population even PD patients were applied to our exclusion criteria which are very strict to exclude any other possible factors that could be cause of secondary RLS. Although it is believed that RLS in PD patients evolve with different mechanism than RLS in general population, it is not clear what risk factors of RLS in PD patients are apart from known risk factors.
Although RLS pathophysiology are tried to be explained by different mechanism such as dopaminergic dysfunction, spinal disinhibiting and iron metabolism, it is still unclear. Also, pathophysiology of RLS in ESRD patients who are treated both HD and PD is unknown. One of mechanisms that are the most emphasized is anemia and iron deficiency. In fact, controversial results have been reported on the relationship between lower serum hemoglobin, ferritin, iron and RLS in ESRD patients, showing both the absence [16,19,30,35] and presence of this association [23,36]. Especially, more recent studies have failed to show this association, but this might be caused by the routine use of high-dose intravenous iron and erythropoietin in modern dialysis management [29]. In current study, no significant differences were found in hemoglobin level, iron and ferritin levels in serum, total iron binding capacity, transferrin saturation and use of erythropoietin between PD patients with and without RLS.
Although prevalence of RLS has been reported to be higher in female gender and advanced age in general population, relationship between presence of RLS and age, gender in ESRD patients has not been exactly known. Some authors [23] have suggested that RLS prevalence in uremic patients is more in female gender and related with advanced age whereas others [16] and the current study haven’t shown this relation.
Relationship between smoking, alcohol consumption and RLS in ESRD patients is controversial. Some studies suggest negatively effect of smoking and alcohol consumption
Table 2. Comparison of demographic, clinical, and biochemical parameters between patients with RLS and those without RLS.
RLS: Restless legs syndrome, PET: peritoneal equilibration test.
on RLS in ESRD patients [37] whereas the others and our study have not demonstrated this relation [30,38,39].
The role of serum calcium, phosphorus and intact parathormone levels in uremic RLS are controversial. Until today, relationship of RLS with high calcium [40], abnormal phosphorus [30], low [16] and high levels of PTH [21] have been described in uremic RLS patients. Moreover an anecdotal improvement of symptoms after parathyroidectomy have been described in uremic RLS [41].
On the other hand, there are also studies that lacked to show any significant difference on calcium, phosphorus and PTH levels [19,37]. In this study, no significant difference was found between ESRD patients with and without RLS in serum calcium, phosphorus and PTH levels.
It is not known which factors associated with dialysis play a role in the development of RLS in ESRD patients. For example, there are contradictory study results assessing affect of dialysis duration on presence of RLS [16,21,42]. The other dialysis parameter that is thought related to RLS is level of urea Kt/V. Urea Kt/V is accepted as the optimal method for assessing the adequacy of dialysis. Some studies have suggested that RLS might represent a marker of inadequate dialysis in ESRD patients [37,43]. However, results of the present study showed any correlation neither dialysis duration nor level of Kt/v urea between PD patients with and without RLS, concordant with some previous studies [32,44].
Although in previous studies it was shown that vitamin B12 and folic acid are associated with RLS, our study did not confirm that in PD patients with RLS. However, in this study RLS was found to be more common in patients who are not taking B complex vitamins + folic acid supplement.
This study is the first and unique study that evaluates the prevalence of RLS on PD patients and describes clinical and biochemical parameters which may be related to RLS in patients under PD due to ESRD in Turkish patients. In fact the most important aspect of the study is that a prevalence study after other risk factors for RLS are excluded.
RLS is a very important sleep related sensorimotor disorder that decreases life quality and increases morbidity and mortality rates in PD patients. Therefore RLS must be diagnosed and treated at early period. Also, vitamin B and folic acid supplements could be used to decrease RLS prevalence in PD patients.